Back to News

GVK Biosciences Licenses its Toxicity Database to AstraZeneca

Hyderabad, India — February 18, 2008 — GVK Biosciences (GVK BIO) announced that it has licensed its Mechanism Based Toxicity Database (MBT) to AstraZeneca. MBT has over 13,000 drug and drug like compounds, their routes of metabolism, toxic indications and the numerical values of the measures of toxicity. The data has been manually curated from over 35,000 individual references. The license represents an extension of the existing license of all the GVK BIO Target and Drug databases. The GVK BIO Databases contain over 3.2 million compounds manually curated from patents and journals and represent over 7 million quantitative SAR data points.

Sreeni Devidas, Vice President Business Development, GVK BIO said: “We are excited to extend our relationship with AstraZeneca. The MBT provides easily accessible information on known toxic effects of over 13,000 compounds from the literature, which will be made available to researchers in AstraZeneca”.

Informatics at GVK BIO
The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies.

About GVK BIO
GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to global pharmaceutical and biotech companies. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Gurgaon.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $29.559 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

Contact
E: corpcomm@aragen.com